Xenetic Biosciences, Inc. (NASDAQ:XBIO) shares were flat Wednesday. The company, a biopharmaceutical firm, focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the quarter ended March 31, 2026 and provided a corporate update on the advancement of its innovative DNase oncology platform.
The company generated robust translational data supporting the DNase I platform across multiple oncology settings. It also completed process improvement and analytical development activities supporting future clinical manufacturing readiness
Xenetic also established translational and biomarker insights intended to help inform and de-risk future clinical trial design. What’s more, its collaboration partner received approval from Israeli Ministry of Health to conduct investigator-initiated exploratory study of DNase I in combination with anti-CD19 CAR T cells in large B-cell lymphoma.
Royalty revenue for the three months ended March 31, 2026 increased approximately 36% to approximately $0.8 million, compared to approximately $0.6 million for the comparable prior year period, primarily driven by increased royalty payments recognized under the Company's sublicense agreement with Takeda Pharmaceuticals Co. Ltd.
Research and development expenses for the three months ended March 31, 2026 decreased approximately 25% to approximately $0.7 million from approximately $0.9 million for the comparable prior year period, primarily due to lower preclinical and exploratory study costs, partially offset by increased manufacturing development efforts supporting the Company's DNase I program.
XBIO shares eased 0.2%, to $3.02.
Related Stories
